Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts.
Conditions
Interventions
Renin-Angiotensin (RAAS) alone
Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Locations
2
United States
Georgia Nephrology Research Institute
Lawrenceville, Georgia, United States
Nelson Kopyt, MD
Bethlehem, Pennsylvania, United States
Start Date
October 1, 2018
Primary Completion Date
October 1, 2022
Completion Date
October 1, 2024
Last Updated
October 28, 2022
NCT06660277
NCT06314503
NCT06863194
NCT06867471
NCT06833541
NCT04931537
Lead Sponsor
James A. Tumlin, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions